Samsung Bioepis Presents Post-hoc Analysis of P-III Clinical Trial for SB15, a Proposed Biosimilar to Eylea (Aflibercept) at EURETINA 2023
Shots:
- The company highlighted the post-hoc analysis from the P-III clinical study evaluating 3 monthly injections (2mg) of SB15 vs aflibercept followed by treatment q8w for ~48wk. in a ratio (1:1) in 449 study patients
- The results showed that switching to SB15 from aflibercept maintained comparable clinical efficacy and safety in treating nAMD patients & confirmed biosimilarity between these agents before and after switching
- Samsung Bioepis and Biogen signed an exclusive commercialization agreement in Nov 2019 for two ophthalmology biosimilar candidates, SB11/Byooviz (ranibizumab) and SB15 (aflibercept) in major markets globally
Ref: Globenewswire | Image: Samsung Bioepis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
